JPRN-jRCT2080221485未知2 期
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
适应症
试验速览
- 阶段
- 2 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Men and women. Women must be surgically sterilized/postmenopausal or use double barrier method contraception
- •- 6 months history of asthma according to ATS definition
- •- Prescribed daily dose of ICS and LABA for at least 3 months prior to Visit 2
- •- Pre-bronchodilator FEV1 of 40 to 85 % of predicted normal
- •- A total ACQ5 score of 1.5 or more
排除标准
- •- Respiratory infection significantly affecting the asthma
- •- Any significant disease and disorder that may put the patient at risk or influence study results
- •- Any clinically relevant abnormal findings
- •- A smoking history of more than 10 pack years
- •- Intake of oral, rectal or parenteral glucocorticosteroids
研究者
相似试验
进行中（未招募）
不适用
/AHeterozygous Familial HypercholesterolaemiaMedDRA version: 14.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001483-21-CZKaro Bio AB1,050
招募中
3 期
A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long-term Phase III Trial Assessing the Safety and Efficacy of 50 microgram and 100 mircrogram/day of eprotirome in Patients with Heterozygous Familial Hypercholesterolaemia who are on Optimal Standard of Care100274241001331710003216familial hypercholesterolemiaNL-OMON36068Karo Bio AB160
进行中（未招募）
不适用
A clinical study on patients suffering from high level cholesterols. The aim is to evaluate safety and efficacy of a new medicinal drug.Heterozygous Familial HypercholesterolaemiaMedDRA version: 14.0Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001483-21-ATKaro Bio AB1,050
进行中（未招募）
不适用
Eprotirome in Patients with HeFH who are on Optimal Standard of CareEUCTR2011-001483-21-GBKaro Bio AB1,050
进行中（未招募）
1 期
A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long-term Phase III Trial Assessing the Safety and Efficacy of 50 µg and 100 µg/day of eprotirome in Patients with Heterozygous Familial Hypercholesterolaemia who are on Optimal Standard of Care - AKKAHeterozygous Familial HypercholesterolaemiaMedDRA version: 14.1Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001483-21-DKKaro Bio AB